HemaSphere (Oct 2020)

Controversies in the Treatment of Peripheral T-cell Lymphoma

  • Emmanuel Bachy,
  • Alessandro Broccoli,
  • Claire Dearden,
  • Laurence de Leval,
  • Philippe Gaulard,
  • Raphael Koch,
  • Franck Morschhauser,
  • Lorenz Trümper,
  • Pier Luigi Zinzani

DOI
https://doi.org/10.1097/HS9.0000000000000461
Journal volume & issue
Vol. 4, no. 5
p. e461

Abstract

Read online

Abstract. Peripheral T-cell lymphomas are a heterogeneous group of rare diseases with an aggressive behavior and dismal prognosis. Their classification is complex and still evolving, and several biomolecular markers now help refine the prognosis of specific disease entities, although still have limited impact in tailoring the treatment. First-line treatment strategies can cure only a minority of patients and relapsed-refractory disease still represents the major cause of failure. Frontline autologous transplantation may have an impact in the consolidation of response; however, its role is still questioned as far as complete responses obtained after induction chemotherapy are concerned. Newer drugs are now being evaluated in clinical trials, but effective salvage strategies for those who experience treatment failures are lacking. Here we review and discuss the most controversial aspects of diagnosis and treatment of peripheral T-cell lymphomas.